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Abstract
Background: The contribution of smoking to rheumatoid arthritis (RA) is hypothesized to be mediated through
formation of anti-citrullinated protein antibodies (ACPA). In RA, however, autoantibodies such as ACPA, rheumatoid
factor (RF), and anti-carbamylated protein antibodies (anti-CarP) often occur together, and it is thus unclear whether
smoking is specifically associated with some autoantibodies rather than others. We therefore investigated whether
smoking is only associated with ACPA or with the presence of multiple RA-related autoantibodies.
Methods: A population-based Japanese cohort (n = 9575) was used to investigate the association of smoking with
RF and anti-cyclic citrullinated peptide antibodies (anti-CCP2) in individuals without RA. Furthermore, RA patients
fulfilling the 1987 criteria from three early arthritis cohorts from the Netherlands (n = 678), the United Kingdom
(n = 761), and Sweden (n = 795) were used. Data on smoking, RF, anti-CCP2, and anti-CarP were available. A total
score of autoantibodies was calculated, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated
by logistic regression.
Results: In the population-based non-RA cohort, no association was found between smoking and one autoantibody
(RF or anti-CCP2), but smoking was associated with double-autoantibody positivity (OR 2.95, 95% CI 1.32–6.58).
In RA patients, there was no association between smoking and the presence of one autoantibody (OR 0.99, 95%
CI 0.78–1.26), but smoking was associated with double-autoantibody positivity (OR 1.32, 95% CI 1.04–1.68) and
triple-autoantibody positivity (OR 2.05, 95% CI 1.53–2.73).
Conclusions: Smoking is associated with the concurrent presence of multiple RA-associated autoantibodies rather
than just ACPA. This indicates that smoking is a risk factor for breaking tolerance to multiple autoantigens in RA.
Keywords: Rheumatoid arthritis, Smoking, Anti-citrullinated protein antibodies, Rheumatoid factor, Anti-carbamylated
protein antibodies, Risk factor
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease, characterized by synovial inflammation and joint
destruction [1]. Current concepts of the pathophysiology
of RA are based on associations between RA and risk
factors [2]. Among the genetic risk factors, the human
leukocyte antigens (HLA)-DRB1 locus with the shared
epitope (SE) alleles is associated with the largest effect
size [3]. The most prominent environmental risk factor
for RA is smoking. Autoantibodies such as rheumatoid
factor (RF) are present in the majority of RA patients
and are known to develop years before disease onset
[4, 5]. Smoking was originally described to be associated
with RF-positive RA [6–8]. The discovery of anti-
citrullinated protein antibodies (ACPA) led to a paradigm
shift in the field of RA risk factor analysis, because many
known predisposing factors were found to be specifically
associated with ACPA-positive RA rather than ACPA-
negative RA [9–11]. This particularly applies to the HLA
SE alleles and smoking, for which a gene–environment
interaction has been described for ACPA-positive RA [12,
13]. Because of this striking finding, smoking was incorpo-
rated into a now widely adopted pathophysiological model
explaining the processes underlying ACPA formation [14].
According to this model, smoking exerts its influence
many years before disease onset by causing citrullination
of proteins in the lungs. An autoimmune response against
these proteins then leads to the production of ACPA in
HLA SE-positive individuals.
While this hypothesis is based on a specific link between
smoking, HLA SE alleles, and ACPA, smoking has also
been reported to be associated with other RA-related
autoantibodies. In mice and humans with chronic lung
disease, smoking has been reported to induce production
of RF rather than ACPA [15]. Furthermore, recent re-
search in a population-based cohort in Japan revealed
in non-RA healthy individuals that there was a dose-
dependent association of smoking not only with high
levels of ACPA but also with high levels of RF [16].
This raised the question whether the association of
smoking with RA is limited to ACPA-positive RA, or
whether smoking is associated with other autoantibodies
and/or multiple autoantibodies as well.
To address this question, we first investigated the
association of smoking with RF and anti-CCP2 in a
population-based cohort of healthy individuals because
smoking presumably exerts its influence years before
disease onset [4, 5, 17]. Next, we investigated the asso-
ciation of smoking and anti-CCP2, IgM-RF, and anti-
carbamylated protein antibodies (anti-CarP) in RA
patients from three independent cohorts. Anti-CarP is a
more recently described autoantibody present in estab-
lished RA as well as in the pre-RA phases [5, 18–23].
Finally, we also studied whether smoking might be
associated with the breadth of the autoimmune response,
reflected by the number of autoantibodies. Furthermore,
we looked at anti-nuclear antibodies (ANA) to see
whether the association between smoking and autoanti-
bodies is specific for RA-related autoantibodies or exists
for autoantibodies in general.
Methods
Populations
Data on non-RA subjects were derived from the Japanese
Nagahama Prospective Genome Cohort for Compre-
hensive Human Bioscience (Nagahama study) [16]. Vol-
unteers without autoimmune disease from Nagahama
city were recruited from 2008 to 2010.
Original individual patient data of RA patients were
used from three independent early arthritis cohorts from
the United Kingdom (n = 678), the Netherlands (n = 769),
and Sweden (n = 795). The UK dataset originated from
the Norfolk Arthritis Register (NOAR) [24]. Data on
Dutch RA patients were provided from the Leiden Early
Arthritis Clinic (EAC) [25]. The Swedish data originated
from the Better Anti‐Rheumatic Farmaco-Therapy
(BARFOT) cohort [26]. Inclusion criteria and details of
these cohorts have been described elsewhere [24–26].
From each cohort, patients who fulfilled the 1987 cri-
teria for RA with disease duration shorter than 2 years
and for whom information on smoking and all three
autoantibodies under study was available were included
in the current analysis.
The protocol of each cohort was approved by the rele-
vant local ethics committee and all participants provided
written informed consent.
Smoking
Data concerning smoking were collected at baseline. In
the NOAR, data on smoking history were obtained by
designated study nurses. In the BARFOT, each patient’s
smoking history was assessed by the rheumatologist. In-
formation regarding smoking history in the EAC and the
Nagahama study was obtained using a questionnaire.
Smoking was defined as smoking of cigarettes. In all
cohorts, distinction was made between never smoking
and ever smoking. In addition, for the NOAR, the EAC,
and the BARFOT, information on former smoking versus
current smoking was available. No data on pack-years
were available.
Genotyping
For the majority of patients in the EAC (n = 652) and
the NOAR (n = 544), HLA-DRB1 genotyping data were
available. DNA was collected at baseline for genotyping
by polymerase chain reaction and hybridization to
sequence-specific oligonucleotides as described previ-
ously [27]. The HLA-DRB1*01:01, HLA-DRB1*01:02,
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HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05,
HLA-DRB1*04:08, HLA-DRB1*10:01, and HLA-DRB1*
14:02 alleles were classified as the SE alleles.
Serological measurements
All measurements were performed in serum samples
collected at baseline, except for anti-CarP in the
NOAR which was measured in serum taken within the
first year of follow-up. A commercial enzyme-linked
immunosorbent assay was used to measure anti-cyclic
citrullinated peptide antibodies (anti-CCP2); Diastat
(Axis-Shield) for the NOAR; MesaCup for the Nagahama
study; and Eurodiagnostica for the EAC and the BARFOT.
Cutoff values were specified by the manufacturer.
IgM-RF was measured by commercial tests: ELISA in
the EAC, agglutination test (SERODIA-RA) in the BAR-
FOT, and latex turbidimetric immunoassay in the NOAR
and the Nagahama study. Cutoff values were specified
by the manufacturer.
IgG-anti-CarP antibodies were measured in Leiden for
all cohorts with carbamylated fetal calf serum (FCS) as
antigen using in-house ELISAs. The cutoff value for a
positive response was established as the mean plus two
times the standard deviation (SD) of the specific anti-
CarP reactivity of healthy controls [18].
ANA were determined by indirect immunofluorescence
on Hep-2 cells. Titers above 1:40 were considered positive
in the EAC. Titers above 1:80 were considered positive in
the Nagahama study [28].
Furthermore, in a random selection of patients from
the EAC cohort (n = 386), serum total IgG levels were
measured using the Human IgG-ELISA Quantitation
Set (Bethyl Laboratories, USA) according to the manu-
facturer’s instructions.
Statistical analysis
The association between smoking (ever versus never)
as the explanatory variable and the presence of auto-
antibodies as the outcome (or dependent) variable was
assessed by logistic regression analysis, used to calcu-
late odds ratios (ORs) and 95% confidence intervals
(95% CIs). Seronegative nonsmoking patients were used
as the reference group. The total score of autoanti-
bodies was calculated. Ordinal regression was used to
assess the association between smoking and the num-
ber of autoantibodies.
Subsequently, a pooled analysis was performed using
individual patient data from the respective cohorts. A
random-effects model was used because statistical het-
erogeneity was present (p < 0.10 using the Q statistic) in
some analyses. Correction for levels of anti-CCP2 and
RF was applied using log10-transformed autoantibody
levels because of skewness of these levels.
In the EAC and the NOAR, biological interaction be-
tween smoking and HLA SE alleles, defined as the devi-
ation from additivity of the corresponding estimates of
the outcome, was assessed by three measures: RERI,
relative excess risk due to interaction; AP, the attribut-
able proportion due to interaction; and S, the synergy
index. These measures indicate a significant biological
interaction if they differ from 0 (RERI and AP) or from
1 (S) [29]. To obtain the parameter estimates needed for
calculating these three measures, a logistic regression
model was fitted and interaction data were analyzed
using Microsoft Windows Excel 2007 [30].
Antibody levels among different subgroups were com-
pared using Mann–Whitney U tests. The analyses were
performed per cohort using SPSS version 22.0. For the
pooled analysis MedCalc software was used. p < 0.05 was
considered statistically significant.
Results
Smoking and autoantibody positivity in a population-
based non-RA cohort
Smoking most likely exerts its effect many years before
disease development, so we first investigated the associ-
ation between smoking and RA-related autoantibodies
in a non-RA population-based cohort of healthy individ-
uals: the Nagahama study.
Of the 9575 participants in this study, 35% (n = 3356)
ever smoked, 1.7% (n = 167) were anti-CCP2-positive,
and 5.3% (n = 514) were RF-positive. There was no asso-
ciation between smoking and the presence anti-CCP2 or
RF in these healthy individuals. However, smoking was
significantly associated with the presence of both of
these autoantibodies (Table 1). This observation suggests
that smoking may lead to the development of multiple
autoantibodies, rather than one specific autoantibody.
Table 1 Odds ratios for RF and anti-CCP2 autoantibodies in association with smoking in a population-based non-RA cohort
RF–anti-CCP2– (n = 8836) RF+anti-CCP2– (n = 572) RF–anti-CCP2+ (n = 125) RF+anti-CCP2+ (n = 42)
Smoking ever (%) 3117 (35.3) 178 (31.1) 39 (31.2) 22 (52.4)
Smoking never (%) 5719 (64.7) 394 (68.9) 86 (68.8) 20 (47.6)
Odds ratio (95% CI) 1 (reference) 0.94 (0.75–1.18) 0.97 (0.6–1.58) 2.95 (1.32–6.58)*
p value – 0.23 0.48 <0.001*
*Significant values (p < 0.05)
anti-CCP2 anti-cyclic citrullinated peptide antibodies, CI confidence interval, RA rheumatoid arthritis, RF rheumatoid factor
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Association between smoking and autoantibody-positive RA
Next we studied the association of smoking with auto-
antibodies in RA patients from three independent early
arthritis cohorts. The characteristics of the early arthritis
cohorts are presented in Table 2. The proportion of ever
smokers between the different cohorts was similar (p =
0.25). The prevalence of all autoantibodies was slightly
lower in the NOAR compared with the EAC and the
BARFOT. In all cohorts, the largest autoantibody-positive
subgroup was the triple-positive subgroup.
When the association between smoking and the sep-
arate autoantibodies (RF, anti-CCP2, and anti-CarP)
was analyzed irrespective of the presence of other auto-
antibodies, a significant association was found for each
autoantibody in all cohorts (Table 3).
Based on our findings in the Nagahama study, we then
calculated the total number of autoantibodies per patient
to investigate whether smoking may be associated with
the number of autoantibodies present. The association
between smoking and the number of autoantibodies is
presented in Table 4, which revealed no association of
smoking with either one or two autoantibodies but a sig-
nificant association with triple-autoantibody positivity.
Ordinal regression analysis showed a significant
association between smoking and the number of auto-
antibodies in all cohorts (NOAR, p = 0.005; EAC, p =
0.001; BARFOT, p < 0.001), indicating a significantly
stronger association in patients with many versus few
autoantibodies.
Next, a pooled analysis of the three aforementioned
early arthritis cohorts was performed. Although no
association between ever smoking and single seropositiv-
ity could be detected (Fig. 1a), ever smoking was associ-
ated with double-autoantibody-positive RA (Fig. 1b) and
triple-autoantibody-positive RA (Fig. 1c). When compar-
ing double-positive patients with triple-positive patients,
there was a trend towards a stronger association in
triple-positive patients, although this did not reach stat-
istical significance (Fig. 1d).
To see whether the association between smoking and
the number of autoantibodies was caused by the increas-
ing prevalence of one specific autoantibody among the
patients with a higher autoantibody number, a subgroup
analysis of all different autoantibody combinations was
performed (Table 5). In the pooled analysis of the vari-
ous subgroups, no significant associations were found in
patients positive for one single autoantibody, be it anti-
CCP2, RF, or anti-CarP. A significant association with
smoking was found, however, for the anti-CCP2+RF
+anti-CarP– subgroup and the triple-positive subgroup
compared with the triple-seronegative group. This result
again suggests that smoking is associated with the pres-
ence of multiple autoantibodies rather than with a spe-
cific autoantibody. It is remarkable that compared with
the seronegative RA patients, the prevalence of smoking
was consistently higher in all RF-positive subgroups, but
not in all anti-CCP2-positive subgroups. To investigate
the added value of RF, we compared the triple-positive
group with the anti-CCP2+RF–anti-CarP+ group. This
analysis revealed a significant OR of 2.24 (95% CI 1.30–
3.84). In contrast, no significant association was ob-
served when the added value of anti-CCP2 (OR 1.18,
95% CI 0.60–2.31) or anti-CarP (OR 1.50, 95% CI 0.91–
2.46) in double-positive versus triple-positive patients
was analyzed. Together, these data indicate that the
strong association of smoking with the triple-positive
subgroup is significantly influenced by the presence of RF.
Levels of autoantibodies and smoking
To examine whether the association between smoking
and triple-positive RA might depend on levels of the
autoantibodies, we used ordinal regression to adjust for
autoantibody levels. A significant association between
smoking and the number of autoantibodies was still
present after correction for anti-CCP2-levels in the EAC
(p = 0.020) and the NOAR (p = 0.026), but not in the
BARFOT (p = 0.23). However, in all three cohorts the
association between smoking and the number of auto-
antibodies was lost after correction for RF levels: EAC
(p = 0.64), NOAR (p = 0.18), and BARFOT (p = 0.98).
Past versus current smoking
To investigate whether the timing of smoking exposure
might affect the association with RA-related autoanti-
bodies, we performed a subgroup analysis of RA
Table 2 Prevalence of smoking and autoantibodies in RA
patients from three different early arthritis cohorts
NOAR EAC BARFOT
RA patients, n 678 769 795
Ever smokers 432 (64) 415 (54) 471 (59)
Anti-CarP-positive 182 (27) 349 (45) 279 (35)
Anti-CCP2-positive 247 (36) 404 (53) 456 (57)
RF-positive 277 (41) 442 (58) 448 (56)
Anti-CCP2–RF–Anti-CarP– 292 (43) 242 (32) 263 (33)
Anti-CCP2+RF–Anti-CarP– 51 (8) 20 (3) 45 (6)
Anti-CCP2–RF+Anti-CarP– 76 (11) 71 (9) 59 (7)
Anti-CCP2–RF–Anti-CarP+ 40 (6) 38 (5) 6 (1)
Anti-CCP2+RF+Anti-CarP– 73 (11) 87 (11) 149 (19)
Anti-CCP2+RF–Anti-CarP+ 15 (2) 27 (4) 33 (4)
Anti-CCP2–RF+Anti-CarP+ 20 (3) 14 (2) 11 (1)
Anti-CCP2+RF+Anti-CarP+ 107 (16) 270 (35) 229 (29)
Data presented as n (%) unless otherwise stated
anti-CarP anti-carbamylated protein antibodies, anti-CCP2 anti-cyclic citrullinated
peptide antibodies, BARFOT Better Anti‐Rheumatic Farmaco-Therapy, EAC
Early Arthritis Clinic, NOAR Norfolk Arthritis Register, RA rheumatoid arthritis,
RF rheumatoid factor
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Table 3 Association of smoking with anti-CCP2, RF antibodies, and anti-CarP in the RA cohorts
Anti-CCP2– Anti-CCP2+ RF– RF+ Anti-CarP– Anti-CarP+
NOAR
N (total) 428 242 398 276 492 182
Ever smokers, n (%) 261 (61) 171 (71) 236 (59) 196 (71) 301 (61) 131 (72)
OR (95% CI) 1 (reference) 1.46 (1.04–2.03)* 1 (reference) 1.68 (1.21–2.33)* 1 (reference) 1.63 (1.12–2.36)*
p value – 0.027* – <0.001* – 0.01*
EAC
N (total) 365 404 327 442 420 349
Ever smokers, n (%) 179 (49) 236 (58) 152 (47) 263 (60) 212 (51) 203 (58)
OR (95% CI) 1 (reference) 1.46 (1.10–1.94)* 1 (reference) 1.69 (1.27–2.26)* 1 (reference) 1.36 (1.03–1.82)*
p value – 0.009* – <0.001* – 0.03*
BARFOT
N (total) 347 448 339 456 516 279
Ever smokers, n (%) 180 (52) 291 (65) 183 (54) 288 (63) 288 (56) 183 (66)
OR (95% CI) 1 (reference) 1.72 (1.29–2.29)* 1 (reference) 1.46 (1.01–1.95)* 1 (reference) 1.51 (1.12 – 2.04)*
p value – <0.001* – 0.009* – 0.008*
*Significant values (p < 0.05)
anti-CarP anti-carbamylated protein antibodies, anti-CCP2 anti-cyclic citrullinated peptide antibodies, BARFOT Better Anti‐Rheumatic Farmaco-Therapy, CI confidence
interval, EAC Early Arthritis Clinic, NOAR Norfolk Arthritis Register, OR odds ratio, RA rheumatoid arthritis, RF rheumatoid factor
Table 4 Odds ratios for presence of anti-CCP2, RF autoantibodies, and anti-CarP according to smoking status
Number of autoantibodies
0 1 2 3
NOAR
N (total) 292 167 108 107
Smoking ever, n (%) 179 (61.3) 97 (58.0) 67 (62.0) 89 (83.2)
Smoking never, n (%) 113 (38.7) 70 (41.9) 41 (38.0) 18 (16.8)
OR (95% CI) 1 (reference) 0.87 (0.59–1.29) 1.03 (0.65–1.63) 3.12 (1.79–5.46)*
p value – 0.50 0.89 <0.001*
EAC
N (total) 242 129 128 270
Smoking ever, n (%) 113 (46.7) 67 (51.9) 70 (54.7) 165 (61.1)
Smoking never, n (%) 129 (53.3) 62 (48.1) 58 (45.3) 105 (38.9)
OR (95% CI) 1 (reference) 1.23 (0.80–1.89) 1.38 (0.90–2.12) 1.79 (1.26–2.55)*
p value – 0.34 0.14 0.001*
BARFOT
N (total) 263 110 193 229
Smoking ever, n (%) 138 (52.5) 58 (52.7) 121 (62.7) 154 (67.2)
Smoking never, n (%) 125 (47.5) 52 (47.3) 72 (37.3) 75 (32.8)
OR (95% CI) 1 (reference) 1.01 (0.65–1.58) 1.52 (1.04–2.22)* 1.86 (1.29–2.69)*
p value – 0.96 0.03* 0.001*
*Significant values (p < 0.05)
anti-CarP anti-carbamylated protein antibodies, anti-CCP2 anti-cyclic citrullinated peptide antibodies, BARFOT Better Anti‐Rheumatic Farmaco-Therapy, CI confidence
interval, EAC Early Arthritis Clinic, NOAR Norfolk Arthritis Register, OR odds ratio, RF rheumatoid factor
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patients who smoked at the time of inclusion, called
“current” smokers. The results suggested a stronger as-
sociation between autoantibody positivity and current
smoking than ever smoking in the NOAR (triple-posi-
tive group, OR 4.92 for current smoking versus 3.12
for ever smoking) and in the EAC (OR 2.13 versus
1.79), but not in the BARFOT (see Additional file 1 for
further details). These findings suggest that the timing
of smoking exposure and possibly the amount/dose of
smoking may affect the relationship between smoking
and autoantibodies in RA. Unfortunately, data on
smoking dose in terms of pack-years were not available
Fig. 1 Pooled analysis investigating the association between smoking and the number of autoantibodies. Forest plots with odds ratio (OR)
and 95% confidence interval. a Association of smoking with one autoantibody versus zero autoantibodies. b Association of smoking with two
autoantibodies versus zero autoantibodies. c Association of smoking with three autoantibodies versus zero autoantibodies. d Association of
smoking with three autoantibodies versus two autoantibodies. BARFOT Better Anti‐Rheumatic Farmaco-Therapy, EAC Early Arthritis Clinic, NOAR
Norfolk Arthritis Register
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p value – 0.37 0.16 0.36 0.02* 0.79 0.12 <0.001*
*Significant values (p < 0.05)
anti-CarP anti-carbamylated protein antibodies, anti-CCP2 anti-cyclic citrullinated peptide antibodies, CI confidence interval, OR odds ratio, RF rheumatoid factor
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in all three cohorts, precluding any conclusions on a
dose effect.
Interaction analysis of smoking and SE alleles with
autoantibodies
Because we found that smoking is associated with the
number of autoantibodies rather than just with anti-
CCP2, we then investigated whether the interaction be-
tween the HLA-DRB1 SE alleles and smoking is also
dependent on the number of autoantibodies. First, the
association of SE by itself with the number and differ-
ent subgroups of autoantibodies was investigated in
patients from the EAC and the NOAR for whom HLA
typing was available. This analysis revealed an associ-
ation with anti-CCP2-positive RA, but not with the
number of autoantibodies, confirming previous findings
(see Additional file 2 for further details) [10, 31]. Next
we investigated interaction of smoking and HLA-DRB1
SE (see Additional file 3 for further details). In both co-
horts, interaction was most clearly present in the triple-
seropositive subgroup (with at least two of the three
measures indicating significant interaction). An analysis
for all subgroups of autoantibodies indicated the absence
of interaction with any of the specific combinations of
autoantibodies, including the ACPA-positive group,
although power was limited in these subgroups. The
exception was the triple-positive subgroup, in which an
interaction was found (see Additional file 4 for further
details).
Smoking in relation to other autoantibodies and IgG levels
To analyze whether smoking was also associated with
other autoantibodies, the association with ANA was in-
vestigated in RA patients from the EAC and non-RA
individuals in the Nagahama study. No association was
found between smoking and ANA positivity in both co-
horts (EAC: OR 1.03, 95% CI 0.75–1.43; Nagahama: OR
0.72, 95% CI 0.63–0.82).
Finally, we examined whether smoking might enhance
antibody production in general by comparing total IgG
levels among ever smokers and never smokers. In RA
patients from the EAC, mean serum total IgG levels did
not differ between ever smokers (10.0 g/l, n = 174) and
never smokers (10.1 g/l, n = 184) (p = 0.51).
Discussion
This study investigated the association of smoking with
the presence of several autoantibodies in RA. To our
knowledge, this is the first study to investigate whether
smoking is associated with a particular autoantibody or
rather with the breadth of the humoral autoimmune re-
sponse. The results reveal that smoking is associated
with the number of RA-related autoantibodies present
rather than specifically with the presence of ACPA.
Smoking predisposes to the development of several
autoantibodies (RF, ACPA, anti-CarP) and does not seem
to affect the total amount of antibodies (total IgG)
produced, but rather the variety of autoantibodies. Fur-
thermore, the interaction between smoking and the
HLA SE alleles was only present in patients with mul-
tiple autoantibodies. These data are highly relevant for
current pathophysiological disease concepts, because
they indicate that smoking must have a broader effect
than leading only to formation of ACPA as often specu-
lated. Smoking rather appears to contribute to the
formation of an autoimmune response against several
RA-associated autoantigens.
Our data are compatible with and provide an interest-
ing new perspective on recent studies describing that,
during RA disease development, smoking appears to be
most important for the development of autoantibodies,
whereas the contribution of the HLA SE alleles is found
later in time, when they mainly affect the onset of disease
in autoantibody-positive individuals. More specifically, it
was shown in healthy individuals of the Nagahama study
that ACPA were not associated with the presence of SE
alleles [16]. Similar results were found in a Swedish study
analyzing the contribution of smoking and the SE alleles
to the formation of ACPA and ACPA-positive RA, sug-
gesting that SE may have a role in determining which
ACPA-positive individuals develop RA [17]. These data
thus show that smoking predisposes to the develop-
ment of autoantibodies, and are therefore in line with
the aforementioned findings.
Our findings suggest that smoking may have a stron-
ger association with RF than with anti-CCP or anti-CarP
antibodies. In the subgroup analysis the prevalence of
smoking was consistently higher in all subgroups which
are RF-positive, but not in all anti-CCP2-positive sub-
groups or anti-CarP-positive subgroups. Furthermore,
the association of smoking with number of autoanti-
bodies was lost after correction for RF levels. The spe-
cific association between RF and smoking has also been
described in studies of COPD patients, in which 42% of
the patients had RF but none were ACPA-positive [32].
Similarly in mouse studies, chronic cigarette smoke was
found to induce RF production in specific mice strains,
but not ACPA [15]. Ultimately, it is difficult to distin-
guish whether smoking is associated with a higher num-
ber of autoantibodies or higher RF levels because these
are highly correlated features which are both indicative
of a broad, matured autoantibody response.
In our data there was no association between smoking
and IgG level and the presence of ANA in RA patients.
This is in line with reports that smoking is not associ-
ated with autoantibodies in other diseases, such as anti-
thyroid peroxidase (TPO) antibodies in autoimmune
hypothyroidism [33], and that no correlation was found
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between smoking and ANA in COPD patients [34]. The
association between smoking and autoantibodies in
systemic lupus erythematosus (SLE) is still uncertain,
with some studies describing an association with anti-
dsDNA antibodies, which was not replicated in other
investigations [35, 36]. Altogether these observations
suggest that the association of smoking with autoanti-
body formation in other diseases is unclear. Perhaps
this association is therefore specific for RA and RA-
associated autoantibodies.
There are several hypothetical pathophysiological ex-
planations for the observed association between smoking
and the simultaneous presence of various autoantibodies
in RA. On the one hand, smoking may alter the autoan-
tigens against which the immune system reacts, while on
the other smoking may affect the immune system itself.
For example, the metabolism of smoke substances could
generate reactive oxidative species (ROS), which could
lead to the modification of autoantigens and DNA adduct
formation [37, 38]. Another hypothetical mechanism may
involve heat shock proteins (HSPs), which have been
shown to be upregulated in synovial fibroblasts of humans
and mice upon smoke exposure [39]. HSPs in turn have
been found to lead to production of RF in mice [15]. The
interaction between smoking and genetic risk factors spe-
cific for RA may explain that smoking seems to associate
only with RA-related autoantibodies.
Our study investigated the association of smoking with
three autoantibodies: ACPA, RF, and anti-CarP. In our
opinion, anti-CarP is a separate autoantibody, rather
than a subfamily of ACPA, for two reasons. First, previ-
ous studies investigating the crossreactivity of anti-CarP
and ACPA have identified partial crossreactivity, but also
unique nonoverlapping specificity, as is evidenced by the
presence of anti-CarP-antibodies in ACPA-negative pa-
tients [40]. Second, different risk factors have been
found for ACPA and anti-CarP: ACPA is associated with
SE alleles and PTPN22, whereas anti-CarP is not [21].
Limitations of this study are some heterogeneity be-
tween the cohorts with regard to patient recruitment. This
probably explains part of the differences in autoantibody
prevalence. In the NOAR, patient inclusion by general
practitioners may have led to a milder RA phenotype with
patients who are consequently less seropositive, despite
their fulfillment of the 1987 RA criteria. The small patient
numbers in the single autoantibody-positive groups may
have led to lack of power to detect associations. However,
considering the effect size close to 1.0 in the single-
positive groups in the pooled analysis, it seems unlikely
that a larger study population would have yielded a signifi-
cant finding. Anti-CCP2 and RF were measured with dif-
ferent tests in the different cohorts. Literature studies
have shown a high correlation among commercially avail-
able ACPA assays and different RF assays, and therefore it
seems unlikely that this has affected the results [41–44].
In this study we only had data on ever smoking (split into
current and past smoking) versus never smoking. Al-
though it would have been interesting to also investigate a
dose effect of smoking (e.g., by looking at pack-years), this
would not have altered the direction of the association.
This study was performed in European and Asian popula-
tions; therefore replication in different ethnicities is war-
ranted. Finally, one may argue that preferably healthy
controls should be used as the reference category instead
of autoantibody-negative RA patients. However, although
the use of healthy controls would have led to larger effect
sizes for the various autoantibody subgroups, it would not
have altered the relationship as a whole, because the ratio
between the different autoantibody-positive subgroups
would still be the same. Consequently, the strongest effect
would still be present in the triple-seropositive subgroup.
Strengths of the current study include the use of a
unique healthy cohort, as well as several disease cohorts,
thereby capturing the entire spectrum of disease devel-
opment. Furthermore, the fact that our main results
were found in three independent RA cohorts indicates
that these findings are very robust. Finally, the determin-
ation of a novel and promising autoantibody, anti-CarP,
in these three separate cohorts enabled us to investigate
the association between smoking and the number of
antibodies in a more precise and refined manner than
was previously possible.
Conclusion
Smoking is not only associated with the presence of
ACPA, but rather with the concurrent presence of several
autoantibodies in RA. These findings shed new light
on the important role of smoking in disease-specific
immunomodulation in RA.
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